Deferoxamine

• Description:

  Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe (III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5].

• Product Name Alternative:

  Deferoxamine B; Deferriferrioxamine B; Deferrioxamine

• UNSPSC:

  12352211

• Hazard Statement:

  H315, H319, H320

• Target:

  Akt; Apoptosis; Autophagy; HIF/HIF Prolyl-Hydroxylase; Reactive Oxygen Species (ROS)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/deferoxamine.html

• Purity:

  99.76

• Solubility:

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O

• Molecular Formula:

  C25H48N6O8

• Molecular Weight:

  560.68

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139 (3) :695e-706e. |[2]Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172 (3) :738-47.|[3]Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64. |[4]Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57 (3) :198-205.|[5]Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26 (11) :3255.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Chem Biol. 2022 Dec 16;17 (12) :3389-3406.|ACS Nano. 2024 Jul 2;18 (26) :16790-16807.|ACS Nano. 2025 Jun 10;19 (22) :21105-21117.|Acta Pharm Sin B. 2023 Oct;13 (10) :4318-4336.|Acta Pharm Sin B. 2025 Apr;15 (4) :2095-2113.|Acta Pharm Sin B. 2025 Jul;15 (7) :3788-3804.|Adv Mater. 2025 Jun 10:e2504829.|Adv Sci (Weinh) . 2023 May;10 (15) :e2206007.|Adv Sci (Weinh) . 2023 Sep;10 (25) :e2301088.|Adv Sci (Weinh) . 2025 Jul 26:e02052.|Adv Sci (Weinh) . 2025 Nov 6:e07384.|Aging (Albany NY) . 2024 Apr 19;16 (8) :7277-7292.|Am J Chin Med. 2024 May 3:1-19.|Am J Chin Med. 2025;53 (5) :1501-1520.|Animal Model Exp Med. 2025 Jan 23.|Antioxidants (Basel) . 2023 Dec 15;12 (12) :2119.|Apoptosis. 2024 Oct;29 (9-10) :1810-1823.|Autophagy. 2025 Aug 18:1-16.|Biochem Biophys Res Commun. 2022 May 21;605:111-118.|Biochem Biophys Res Commun. 2025 Dec 15:792:152981.|Biochim Biophys Acta Mol Basis Dis. 2024 Dec 30:167645.|Biol Direct. 2024 Nov 11;19 (1) :110.|Biol Direct. 2025 Oct 1;20 (1) :100.|Biomed Pharmacother. 2024 Aug 15:179:117309.|Biomed Pharmacother. 2024 May 10:175:116727.|Biomed Pharmacother. 2024 May:174:116542.|bioRxiv. 2025 March 18.|Bone Res. 2024 Aug 27;12 (1) :47.|Cancer Chemother Pharmacol. 2024 Dec 11;95 (1) :3.|Cancer Lett. 2024 May 1:589:216811.|Cancer Sci. 2025 Aug;116 (8) :2256-2269.|Carbohydr Polym. 2025 Feb 1.|Cell Death Differ. 2025 Mar 25.|Cell Death Dis. 2022 Dec 24;13 (12) :1070.|Cell Death Dis. 2023 Mar 25;14 (3) :211.|Cell Death Dis. 2023 Nov 25;14 (11) :767.|Cell Death Dis. 2024 Mar 1;15 (3) :181.|Cell Death Discov. 2023 Nov 18;9 (1) :419.|Cell Death Discov. 2024 Aug 12;10 (1) :360.|Cell Discov. 2025 Oct 7;11 (1) :81.|Cell Rep Med. 2025 Sep 25:102371.|Cell Rep. 2025 Aug 21;44 (9) :116186.|Cell Rep. 2025 Nov 25;44 (11) :116563.|Cell Signal. 2025 Nov:135:112024.|Chem Biol Interact. 2024 Dec 31:111368.|Chemosphere. 2024 Jul 16:142885.|Clin Transl Med. 2023 Dec;13 (12) :e1494.|Diabet Med. 2023 Jul;40 (7) :e15031.|Ecotoxicol Environ Saf. 2025 Sep 15:303:119045.|Environ Pollut. 2023 Oct 15:335:122278.|Environ Sci Technol. 2025 Oct 28;59 (42) :22423-22438.|Eur J Pharmacol. 2023 Apr 5:944:175516.|Eur J Pharmacol. 2023 Mar 15:943:175569.|Eur J Pharmacol. 2025 Jun 5:996:177424.|Exp Cell Res. 2024 Aug 28:114222.|Exp Eye Res. 2025 Oct:259:110576.|Exp Mol Med. 2025 Nov;57 (11) :2629-2642.|FASEB J. 2023 Jun;37 (6) :e22992.|FASEB J. 2025 Apr 15;39 (7) :e70488.|Free Radic Biol Med. 2023 Apr:199:67-80.|Free Radic Biol Med. 2023 Nov 1:208:348-360.|Free Radic Biol Med. 2023 Sep:206:143-161.|Free Radic Biol Med. 2024 Jul 20:S0891-5849 (24) 00565-3.|Free Radic Biol Med. 2025 Feb 1:227:233-245.|Free Radic Biol Med. 2025 Oct 27:S0891-5849 (25) 01318-8.|Front Pharmacol. 2024 Oct 17:15:1469180.|Immunobiology. 2025 Oct 3;230 (6) :153125.|Int Immunopharmacol. 2024 Nov 13;143 (Pt 3) :113617.|Int Immunopharmacol. 2024 Nov 14;143 (Pt 3) :113614.|Int Immunopharmacol. 2025 May 12:158:114827.|Int J Biol Macromol. 2024 Jul 15:133899.|Int J Biol Sci. 2024 Aug 6;20 (11) :4222-4237.|Int J Mol Sci. 2022 Dec 23;24 (1) :229.|Int J Mol Sci. 2023 Nov 17;24 (22) :16467.|Int J Pharm. 2024 Aug 12:124582.|J Adv Res. 2024 May 24:S2090-1232 (24) 00216-9.|J Adv Res. 2025 Aug:74:589-607.|J Adv Res. 2025 Feb 8:S2090-1232 (25) 00107-9.|J Agric Food Chem. 2022 May 25;70 (20) :6213-6223.|J Agric Food Chem. 2023 Nov 1;71 (43) :16310-16322.|J Appl Toxicol. 2025 Aug;45 (8) :1637-1648.|J Biochem Mol Toxicol. 2024 Apr;38 (4) :e23683.|J Cell Mol Med. 2024 Apr;28 (8) |J Control Release. 2025 Nov 20:389:114450.|J Ethnopharmacol. 2025 Apr 30:119912.|J Exp Clin Cancer Res. 2023 May 19;42 (1) :127.|J Hazard Mater. 2024 Dec 5:480:135952.|J Hazard Mater. 2025 Jul 28:496:139376.|J Immunother Cancer. 2024 Nov 24;12 (11) :e009805.|J Inorg Biochem. 2025 Nov:272:113006.|J Invest Surg. 2025 Dec;38 (1) :2535522.|J Mol Histol. 2025 Jul 31;56 (4) :245.|J Nat Med. 2024 Jun;78 (3) :618-632.|J Neurochem. 2025 Oct;169 (10) :e70246.|J Transl Med. 2025 Feb 28;23 (1) :247.|Kaohsiung J Med Sci. 2023 Jul;39 (7) :699-709.|Liver Int. 2020 Jun;40 (6) :1378-1394.|Liver Int. 2022 Dec;42 (12) :2889-2899.|Mater Today Bio. 2025 Nov 13:35:102547.|Mater Today Phys. 2023 Aug, 36, 101150.|MedComm. 2024 Apr 4;5 (4) :e520.|Mol Carcinog. 2023 Aug;62 (8) :1119-1135.|Mol Cell Biochem. 2025 Jul;480 (7) :4265-4281.|Mol Med Rep. 2026 Jan;33 (1) :24.|Mol Neurobiol. 2025 Apr;62 (4) :4055-4075.|Mol Nutr Food Res. 2024 Apr;68 (7) :e2300343.|Nano Res. 2025 Oct.|Nat Aging. 2025 Jul;5 (7) :1295-1316.|Nat Commun. 2025 Apr 1;16 (1) :3131.|NPJ Precis Oncol. 2024 Aug 21;8 (1) :183.|Oncol Rep. 2023 Jan;49 (1) :16.|Oncol Rep. 2025 Dec;54 (6) :159.|Parasit Vectors. 2023 Nov 16;16 (1) :421.|Phytomedicine. 2024 Dec:135:156139.|Phytomedicine. 2025 Apr 24:142:156804.|Phytomedicine. 2025 Nov 22:150:157584.|Phytomedicine. 2025 Sep 23:148:157326.|PLoS One. 2025 May 22;20 (5) :e0322746.|Poult Sci. 2025 Apr 16;104 (8) :105169. |Redox Biol. 2024 Aug 26:76:103328.|Redox Biol. 2024 Jun:72:103157.|Redox Biol. 2024 Sep:75:103270.|Redox Biol. 2025 May:82:103579.|Redox Biol. 2025 May:82:103597.|Redox Rep. 2025 Dec;30 (1) :2588086.|Res Sq. 2024 Oct 27.|Res Sq. 2025 Aug 08.|Research Square Preprint. 2023 Apr 25.|Research Square Preprint. 2023 Jul 26.|Research Square Preprint. 2023 Oct 13.|Research Square Preprint. 2023 Oct 18.|Sci Rep. 2024 Jun 21;14 (1) :14307.|Sci Rep. 2025 Aug 18;15 (1) :30197.|Sci Rep. 2025 Jan 7;15 (1) :1141.|Sci Total Environ. 2024 Dec 1:954:176497.|SSRN. 2024 Jun 18.|SSRN. 2024 Nov 18.|SSRN. 2025 Feb 21.|SSRN. 2025 Mar 20.|Tissue Cell. 2026 Feb:98:103221.|Water Biol Secur. 2025 Nov 13.|Wayne State University. 2025.|3 Biotech. 2025 Nov;15 (11) :374.|ACS Appl Mater Interfaces. 2018 Feb 21;10 (7) :6180-6189.|ACS Appl Mater Interfaces. 2025 Aug 13;17 (32) :45463-45478.|ACS Chem Biol. 2022 Dec 16;17 (12) :3389-3406.|Acta Pharm Sin B. 2021 Jun;11 (6) :1513-1525.|Acta Pharm Sin B. 2025 Oct 28.|Acta Pharmacol Sin. 2021 Feb;42 (2) :301-310.|Acta Pharmacol Sin. 2021 Jan;42 (1) :160-170.|Acta Pharmacol Sin. 2025 Jul;46 (7) :1974-1989.|Adv Sci (Weinh) . 2021 Mar 8;8 (10) :2004680.|Adv Sci (Weinh) . 2023 Aug;10 (22) :e2206798.|Adv Sci (Weinh) . 2025 Jan 31:e2408845.|Adv Sci (Weinh) . 2025 Nov 7:e18323.|Anal Chim Acta. 2021 Sep 22:1179:338853.|Antioxidants (Basel) . 2023 Dec 19;13 (1) :4.|Antioxidants (Basel) . 2024 Jul 14;13 (7) :840.|Aquaculture. 2024 Jan 30, 579, 740203.|Arch Biochem Biophys. 2023 Aug:744:109691.|Arch Biochem Biophys. 2023 Jul 1:742:109622.|Arch Biochem Biophys. 2025 Jun:768:110366.|Bioact Mater. 2021 Nov 19;13:23-36.|Biochem Biophys Res Commun. 2019 Nov 12;519 (3) :533-539.|Biochem Biophys Res Commun. 2022 Dec 20:635:57-64.|Biochem Biophys Res Commun. 2024 May 28:710:149895.|Biochem Pharmacol. 2021 Apr:186:114436.|Biochem Pharmacol. 2024 May:223:116194.|Biochem Pharmacol. 2025 Jan 18:116763.|Biochem Pharmacol. 2025 Jan 29:116788.|Biochim Biophys Acta Mol Basis Dis. 2025 Jun 17;1871 (7) :167955.|bioRxiv. 2020 Dec 14.|bioRxiv. 2023 Feb 8.|Br J Pharmacol. 2024 Dec;181 (23) :4822-4844.|Br J Pharmacol. 2024 Oct;181 (20) :4067-4084.|Brain Res Bull. 2023 Jan:192:192-202.|Cancer Cell Int. 2024 Jun 3;24 (1) :194.|Cancer Lett. 2024 Apr 10:587:216732.|Cancer Med. 2024 Oct;13 (19) :e70271.|Cancer Nanotechnol. 2023 Oct 21.|Cancers (Basel) . 2022 Jan 11;14 (2) :345.|Carbohydr Polym. 2025 Mar 1:351:123123.|Cell Biol Int. 2024 Oct;48 (10) :1559-1572.|Cell Commun Signal. 2022 Aug 17;20 (1) :124.|Cell Death Differ. 2025 Jun;32 (6) :1071-1085.|Cell Death Dis. 2019 Oct 7;10 (10) :755.|Cell Death Dis. 2020 Mar 13;11 (3) :183.|Cell Death Dis. 2021 Apr 30;12 (5) :426.|Cell Death Dis. 2021 May 19;12 (6) :511.|Cell Death Dis. 2022 Jul 28;13 (7) :653.|Cell Death Dis. 2022 Jul 4;13 (7) :579.|Cell Death Dis. 2023 Jan 12;14 (1) :22.|Cell Death Dis. 2023 Sep 4;14 (9) :588.|Cell Death Dis. 2025 May 19;16 (1) :403.|Cell Death Dis. 2019 Apr 15;10 (5) :331.|Cell Death Discov. 2022 Apr 21;8 (1) :217.|Cell Death Discov. 2022 Mar 22;8 (1) :127.|Cell Death Discov. 2024 Jan 17;10 (1) :34.|Cell Death Discov. 2025 Feb 21;11 (1) :71.|Cell Mol Life Sci. 2022 Jul 4;79 (7) :394.|Cell Mol Life Sci. 2023 May 20;80 (6) :159.|Cell Rep. 2025 Sep 3;44 (9) :116240.|Cell Res. 2018 Dec;28 (12) :1171-1185. |Cell Signal. 2025 Jan 3:111583.|Chem Biol Interact. 2022 Aug 1:362:110004.|Chem Biol Interact. 2023 Oct 27:110788.|Chem Biol Interact. 2024 Feb 25:390:110870.|Chin Herb Med. 2020 Dec 8;13 (1) :105-115.|Colloids Surf B Biointerfaces. 2025 Feb 3:250:114546.|Discov Oncol. 2025 Nov 25;16 (1) :2166.|Drug Des Devel Ther. 2019 Jul 2;13:2135-2144.|EBioMedicine. 2022 Feb;76:103847.|EBioMedicine. 2022 Oct;84:104258.|Ecotoxicol Environ Saf. 2022 Dec 15:248:114333.|Ecotoxicol Environ Saf. 2023 Jul 1:259:115049.|EMBO J. 2023 Oct 16;42 (20) :e113743.|Environ Health. 2025 Nov 28, XXXX (XXX) .|Environ Pollut. 2019 Jul 30;254 (Pt A) :112937.|Environ Pollut. 2023 May 15:325:121434.|Environ Toxicol. 2021 Apr;36 (4) :520-529.|Eur J Pharmacol. 2021 May 5:898:173999.|Eur J Pharmacol. 2023 Oct 15:957:176009.|Eur J Pharmacol. 2024 Apr 15:969:176303.|FEBS J. 2022 Apr;289 (7) :1968-1983.|Fish Shellfish Immunol. 2023 Nov:142:109145.|Fish Shellfish Immunol. 2025 May 13:163:110416.|Food Chem Toxicol. 2022 Aug:166:113255.|Food Chem Toxicol. 2024 Aug 13:114926.|Food Chem Toxicol. 2025 Oct:204:115664.|Free Radic Biol Med. 2020 Nov 20;160:303-318.|Free Radic Biol Med. 2020 Nov 20;160:92-102.|Free Radic Biol Med. 2021 Jun:169:271-282.|Free Radic Biol Med. 2021 Sep:173:29-40.|Free Radic Biol Med. 2022 Aug 1:188:337-350.|Free Radic Biol Med. 2022 Feb 20:180:75-84.|Free Radic Biol Med. 2022 Feb 20:180:95-107.|Free Radic Biol Med. 2022 Nov 20;193 (Pt 1) :202-212.|Free Radic Biol Med. 2023 Dec 14:211:127-144.|Free Radic Biol Med. 2023 May 20:201:76-88.|Free Radic Biol Med. 2023 Nov 1:208:530-544.|Free Radic Biol Med. 2024 Jun 28:S0891-5849 (24) 00542-2.|Free Radic Biol Med. 2025 Aug 1:235:231-247.|Free Radic Biol Med. 2025 Aug 13:240:183-196.|Front Cell Infect Microbiol. 2022 Feb 4;12:825824.|Front Mol Biosci. 2022 Jul 22:9:952608.|Front Oncol. 2021 May 18:11:614778.|Front Oncol. 2022 May 18:12:874900.|Front Pharmacol. 2021 May 10:12:670224.|Genes Dis. 2024 Mar 8;11 (6) :101262.|Heliyon. 2024 Jan 16;10 (2) :e24602.|Heliyon. 2024 Jul 2;10 (13) :e33936.|Hum Reprod. 2021 Mar 18;36 (4) :951-964.|Inflammation. 2025 May 13.|Int J Biol Macromol. 2022 Mar 31:202:657-670.|Int J Mol Med. 2021 Apr;47 (4) :61.|Int J Mol Med. 2022 Feb;49 (2) :17.|Int J Mol Sci. 2024 Feb 20, 25 (5), 2458.|Int J Mol Sci. 2024 Mar 27;25 (7) :3735.|Int J Mol Sci. 2024 Sep 30;25 (19) :10534.|Int J Pharm. 2019 Dec 15;572:118782.|iScience. 2021 Sep 25;24 (10) :103170.|J Adv Res. 2025 Aug:74:429-442.|J Bone Miner Res. 2020 Jun;35 (6) :1163-1173.|J Cancer Res Clin Oncol. 2024 Sep 23;150 (9) :429.|J Cell Physiol. 2020 Apr;235 (4) :3425-3437.|J Cell Physiol. 2020 Feb;235 (2) :1013-1024.|J Cell Physiol. 2021 Apr;236 (4) :2725-2739.|J Cell Physiol. 2020 Apr;235 (4) :3329-3339.|J Cell Sci. 2022 Aug 1;135 (15) :jcs259090.|J Colloid Interface Sci. 2024 Jan;653 (Pt A) :20-29.|J Ethnopharmacol. 2025 May 27:120055.|J Exp Clin Cancer Res. 2021 Jun 23;40 (1) :206.|J Exp Clin Cancer Res. 2023 Jan 5;42 (1) :5.|J Hazard Mater. 2022 Aug 15;436:129043.|J Immunol Res. 2022 Jun 17:2022:6833867.|J Med Chem. 2019 Oct 10;62 (19) :8760-8772. |J Med Virol. 2024 Oct;96 (10) :e29945.|J Nanobiotechnology. 2025 Feb 14;23 (1) :109.|J Nanobiotechnology. 2025 Oct 16;23 (1) :684.|J Neurosci Res. 2023 Jul;101 (7) :1107-1124.|J Nutr Biochem. 2025 Jun 11:109999.|J Pharm Anal. 2023 Jan;13 (1) :99-109.|J Photochem Photobiol B. 2025 Dec:273:113303.|Lab Invest. 2022 Dec;102 (12) :1323-1334.|Life Sci. 2020 Apr 15;247:117425.|Life Sci. 2020 Nov 1;260:118077.|Light Sci Appl. 2024 Oct 31;13 (1) :304.|mBio. 2025 Mar 24:e0012725.|Mol Cell Proteomics. 2023 Jun;22 (6) :100551.|Mol Med Rep. 2025 Aug;32 (2) :215.|Mol Med. 2024 Jun 12;30 (1) :83.|Mol Med. 2024 Nov 5;30 (1) :199.|Mol Neurobiol. 2025 Jul;62 (7) :9271-9289.|Mol Oncol. 2023 Nov;17 (11) :2451-2471.|Mol Ther Oncol. 2025 Apr 14;33 (2) :200983. |Nanoscale Res Lett. 2021 Feb 23;16 (1) :37.|Nanotoxicology. 2022 Nov-Dec;16 (9-10) :829-843.|Nat Cancer. 2025 May;6 (5) :768-785.|Nat Cell Biol. 2024 Sep;26 (9) :1545-1557.|Nat Commun. 2025 Jan 31;16 (1) :1212.|Neurochem Res. 2024 Jul;49 (7) :1703-1719.|Neuroreport. 2022 Nov 2;33 (16) :705-713.|Neurotherapeutics. 2020 Oct;17 (4) :1796-1812.|Oncol Rep. 2021 Nov;46 (5) :240.|Oxid Med Cell Longev. 2021 Feb 10:2021:6670497.|Oxid Med Cell Longev. 2022 Jan 15:2022:9947191.|Oxid Med Cell Longev. 2022 Jul 5:2022:8983667.|Oxid Med Cell Longev. 2023 Jan 31:2023:1367938.|Pharmacol Res. 2021 Aug:170:105701.|Phytomed Plus. 2023 Aug 25, 100482.|Phytomedicine. 2021 Jan;80:153370.|Phytomedicine. 2021 May:85:153551.|Phytomedicine. 2022 May 13;102:154164.|Phytomedicine. 2024 Oct 26:135:156195.|Phytomedicine. 2025 Apr:139:156465.|Phytomedicine. 2025 Jan 25:139:156417.|Phytomedicine. 2025 May 10:143:156840.|Phytomedicine. 2025 Nov 29:150:157633.|Redox Biol. 2020 Jan;29:101402.|Redox Biol. 2021 Jul;43:101977.|Redox Biol. 2022 Apr;50:102257.|Redox Biol. 2024 Dec 5:79:103460.|Redox Biol. 2024 Nov 5:78:103419.|Reprod Toxicol. 2021 Oct:105:156-165.|Research Square Preprint. 2020 Oct.|Research Square Preprint. 2021 Jan.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2023 Nov 17.|Research Square Preprint. 2023 Sep 18.|Research Square Print. 2022 Jul.|Research Square Print. 2023 Feb 20.|Sci Adv. 2022 Mar 4;8 (9) :eabm1896.|Sci Adv. 2023 Nov 15;9 (46) :eadf4345.|Sci Rep. 2025 Jan 8;15 (1) :1351.|Sci Total Environ. 2024 Mar 15:916:170342.|Signal Transduct Target Ther. 2020 May 8;5 (1) :51.|SLAS Discov. 2023 Dec 13:100130.|SLAS Discov. 25 October 2021.|SSRN. 2023 Sep 18.|SSRN. 2024 Apr 23.|SSRN. 2025 Aug 21.|SSRN. 2025 Jun 6.|SSRN. 2025 Sep 16.|Surf Interfaces. 2025 Sep 1.|Talanta. 2024 Jun 1:277:126352.|Theranostics. 2020 Apr 6;10 (11) :5107-5119. |Thromb Haemost. 2024 Jun;124 (6) :568-580.|Toxicol Appl Pharmacol. 2025 Oct 4:505:117590.|Toxicology. 2024 Sep 12:509:153938.|Toxicology. 2025 Feb 5:154078.|Toxics. 2024 Aug 31;12 (9) :644.|Vet Microbiol. 2025 Apr 27:305:110538.|World J Diabetes. 2021 Feb 15;12 (2) :124-137.

• CAS Number:

  [70-51-9]